Drug Profile
AVX 001
Alternative Names: AKH-217; AVX-001Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Avexxin
- Developer Coegin Pharma
- Class Antipsoriatics; Small molecules
- Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis; Plaque psoriasis
- Phase I/II Actinic keratosis
Most Recent Events
- 14 Sep 2022 Coegin Pharma plans a phase IIa trial for Basal cell cancer in first-half of 2023 (Topical) (Coegin Pharma pipeline, September 2022)
- 03 Jan 2022 Coegin Pharma announces intention to submit Clinical trial application for Basal cell cancer (Topical) in Q1 2022 (Coegin Pharma pipeline, January 2022)
- 25 Oct 2021 Phase-I/II clinical trials in Actinic keratosis (In adults, In the elderly) in Denmark (Topical) in October 2021 (EudraCT2021-000934-32)